Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients

BACKGROUND: Semaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer progression and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cancer. Endocrine therapies like tamoxifen and aromatas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Bone Oncol
Hauptverfasser: Göbel, Andy, Kuhlmann, Jan D., Link, Theresa, Wimberger, Pauline, Link-Rachner, Cornelia, Thiele, Stefanie, Dell'Endice, Stefania, Furesi, Giulia, Breining, Dorit, Rauner, Martina, Hofbauer, Lorenz C., Rachner, Tilman D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2019
Schlagworte:
Short Communication
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6461588/
https://ncbi.nlm.nih.gov/pubmed/31011525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2019.100237
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge